| Literature DB >> 31892277 |
Shu-Mei Chen1,2, Feng-Chih Shen2, Jung-Fu Chen2, Wen-Dien Chang3, Nai-Jen Chang1,4,5.
Abstract
Type 2 diabetes mellitus (T2DM) is significantly associated with osteoarthritis (OA). This study investigated the effects of two resistance exercise approaches on glycated hemoglobin (HbA1c) level and function performance. Enrolled were 70 older patients with both T2DM and knee OA. The dynamic group performed resistance exercises with an elastic resistance band. The isometric group underwent isometric contraction exercises. After the 12-week intervention, a significant within-group improvement (all p < 0.001) was observed for the chair stand test (CST; 10.8%, vs. 7.1%), timed up and go (TUG) test (12.6% vs. 7.6%), Western Ontario and McMaster Universities Osteoarthritis (WOMAC) physical function subscale (62.3% vs. 36.1%), and overall WOMAC (54.5% vs. 34.5%) in the dynamic and isometric group, respectively. In addition, in terms of between-group differences, the dynamic group had significant improvements in CST (p = 0.011), TUG (p < 0.001), WOMAC physical function subscale (p = 0.033), and overall WOMAC (p = 0.036) scores compared with the isometric group. However, no significant change in HbA1c was observed in either group. In conclusion, the dynamic resistance exercise significantly improved muscle strength, dynamic balance, and physical function in this comorbid population; however, there was no notable difference in change in HbA1c among different resistance exercises.Entities:
Keywords: diabetes; osteoarthritis; performance; physical activity; therapeutic exercise
Mesh:
Substances:
Year: 2019 PMID: 31892277 PMCID: PMC6981558 DOI: 10.3390/ijerph17010224
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1Dynamic exercise programs with elastic bands.
Baseline characteristics of participants.
| Characteristics | Dyn (n = 30) | Iso (n = 30) |
|
|---|---|---|---|
| Gender | |||
| Male/female, n (%) | 11 (37%)/19 (63%) | 18 (60%)/12 (40%) | 0.325 |
| Age (year) | 65.9 (2.9) | 65.0 (3.1) | 0.233 |
| Body height (cm) | 159.16 (9.75) | 157.29 (7.30) | 0.404 |
| Body weight (kg) | 67.65(12.02) | 69.68(13.53) | 0.542 |
| Body mass index (kg/m2) | 26.68 (4.17) | 28.11 (4.93) | 0.231 |
| Duration of T2DM (year) | 9.13 (7.40) | 11.46 (7.77) | 0.239 |
| HbA1c (%) | 7.24 (1.1) | 7.43 (1.2) | 0.522 |
| Kellgren–Lawrence grade | 1.66 (0.80) | 1.47 (0.82) | 0.343 |
| I, n (%) | 16 (53) | 22 (73) | |
| II, n (%) | 8 (27) | 2 (7) | |
| III, n (%) | 6 (20) | 6 (20) | |
| Taking NSAIDs n (%) | 1 (3.3%) | 1 (3.3%) | 1 |
Dyn = dynamic group, Iso = isometric group. T2DM = Type 2 diabetes mellitus. Values are means with standard deviations (in brackets) unless indicated otherwise. Non-steroidal anti-inflammatory drugs (NSAIDs).
Figure 2CONSORT flow diagram.
Improvements in outcomes after the 12-week intervention between groups.
| Outcomes | Group | Baseline | Post-Intervention | Change | Effect Size | Within-Group, | Between Group, | MDC |
|---|---|---|---|---|---|---|---|---|
|
| Dyn | 7.24 ± 1.14 | 7.06 ± 0.83 | −0.18 | 0.18 | 0.212 | 0.462 | N |
| Iso | 7.43 ± 1.17 | 7.24 ± 1.04 | −0.19 | 0.17 | 0.29 | N | ||
|
| Dyn | 12.08 ± 2.39 | 13.38 ± 3.68 | 1.3 | 0.42 | 0.004 | 0.011 | Y |
| Iso | 10.55 ± 2.64 | 11.30 ± 2.33 | 0.75 | 0.39 | 0.004 | N | ||
|
| Dyn | 9.45 ± 1.73 | 8.25 ± 1.50 | −1.2 | 0.74 | <0.001 | <0.001 | Y |
| Iso | 10.61 ± 1.69 | 9.8 ± 1.42 | −0.82 | 0.51 | 0.002 | N | ||
|
| ||||||||
|
| Dyn | 2.93 ± 3.16 | 1.56 ± 2.12 | −1.37 | 0.51 | 0.001 | 0.48 | Y |
| Iso | 2.86 ± 2.40 | 1.93 ± 1.91 | −0.93 | 0.43 | 0.004 | N | ||
|
| Dyn | 1.2±1.10 | 0.93 ± 0.83 | −0.29 | 0.29 | 0.058 | 0.549 | N |
| Iso | 1.1 ± 1.23 | 0.79±0.82 | −0.31 | 0.29 | 0.174 | N | ||
|
| Dyn | 7.67 ± 6.89 | 2.89 ± 3.27 | −4.78 | 0.89 | <0.001 | 0.033 | Y |
| Iso | 7.93 ± 8.19 | 5.07 ± 5.47 | −2.86 | 0.41 | 0.007 | Y | ||
|
| Dyn | 11.81 ± 10.32 | 5.37 ± 5.52 | −6.44 | 0.78 | <0.001 | 0.036 | Y |
| Iso | 11.90 ± 11.21 | 7.79 ± 7.22 | −4.11 | 0.43 | 0.004 | Y |
Dyn = dynamic group, Iso = isometric group; CST = 30-s chair stand test; TUG = 3-m timed up-and-go test; Changes indicates from baseline to post-intervention; &: nonsignifcant difference in all parameter at baseline # significant group main effect, p < 0.05; Y: exceeded MDC: minimum detectable change; N: Not exceeded MDC.
Figure 3Improvements in HbA1C, CST, TUG, and WOMAC after the 12-week intervention between groups. Dyn = dynamic group, Iso = isometric group. * vs baseline (p < 0.05) # vs Iso (p < 0.05).